Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | PHASE1/PHASE2 | COMPLETED | 44 | — | — | Dec 1, 2020 | Dec 1, 2024 | Feb 11, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| LYT-200 | DRUG | monoclonal antibody (mAb), targeting galectin-9 protein |
| Tislelizumab | DRUG | anti-PD-1 monoclonal antibody |
| Gemcitabine/nab-paclitaxel | DRUG | chemotherapy |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |